Valuation : Realcan Pharmaceutical Group Co., Ltd.

Market Cap 4.63B 690M 593M 560M 510M 953M 65.97B 962M 6.67B 2.57B 33.46B 2.59B 2.53B 106B P/E 2024
217x
P/E 2025 322x
Enterprise Value 5.49B 818M 704M 664M 605M 1.13B 78.22B 1.14B 7.91B 3.04B 39.68B 3.07B 3.01B 126B EV / Sales 2024
0.76x
EV / Sales 2025 0.77x
Free-Float
68.49%
Yield 2024
0.37%
Yield 2025 0.06%
08-20 Realcan Pharmaceutical Group Co., Ltd. Approves the Election of Lv Kaiqiang and Wu Bin as Independent Director CI
08-20 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-19 Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2025 for A shares, Payable on 30 June 2026 CI
04-24 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 30, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-07 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
11-06 Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on November 11, 2024, has closed with 34,638,659 shares, representing 2.31% for CNY 101.48 million. CI
25-10-29 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-10-13 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
25-08-25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-07-02 Realcan Pharmaceutical Vice President Detained MT
25-07-02 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
1 day-2.48%
1 week-5.69%
Current month-0.94%
1 month+3.62%
3 months+15.38%
6 months-0.63%
Current year-2.17%
1 week 3.09
Extreme 3.09
3.37
1 month 2.96
Extreme 2.96
3.9
Current year 2.38
Extreme 2.38
4.11
1 year 2.38
Extreme 2.38
4.69
3 years 2.05
Extreme 2.05
4.69
5 years 2.05
Extreme 2.05
6.73
10 years 2.05
Extreme 2.05
18.26
Manager TitleAgeSince
Director of Finance/CFO 56 2021-04-25
President 61 2023-05-25
Corporate Officer/Principal 40 2019-10-29
Director TitleAgeSince
Chairman 61 2009-11-20
Director/Board Member 43 2009-11-20
Chairman 48 2019-10-07
Date Insider Type Main position Quantity % Market Cap. Importance
5/12/23 Sell

Founder

15,000,000 1.2902%
3/30/23 Sell

Founder

13,040,000 1.1260%
3/30/23 Sell

Chairman

2,000,000 0.1727%
Change 5-day change 1-year change 3-year change Capi.($)
-2.48%-5.69%+7.88%-6.53% 708M
-1.10%-4.30%+24.85%+108.01% 104B
-1.52%-4.87%+58.42%+163.57% 55.82B
-1.12%-2.58%-12.58%+256.76% 22.15B
-1.03%-0.24%-10.68%-7.64% 8.2B
-1.33%-1.88%-37.38%-28.50% 7.05B
+0.96%-0.50%+5.65%+30.96% 6.74B
-1.27%+1.04%-16.49%-26.19% 6.25B
-0.66%-0.48%-3.50%+19.34% 5.12B
+2.56%+14.29%+393.52%+561.16% 5B
Average -0.76%+0.25%+40.97%+107.09% 22.1B
Weighted average by Cap. -1.08%-1.56%+32.14%+129.98%

Financials

2024 2025
Net sales 7.97B 1.19B 1.02B 963M 877M 1.64B 113B 1.66B 11.47B 4.41B 57.56B 4.46B 4.36B 183B 7.3B 1.09B 935M 882M 804M 1.5B 104B 1.52B 10.51B 4.04B 52.72B 4.08B 3.99B 167B
Net income 20.62M 3.07M 2.64M 2.49M 2.27M 4.25M 294M 4.28M 29.69M 11.43M 149M 11.54M 11.29M 473M 16.07M 2.39M 2.06M 1.94M 1.77M 3.31M 229M 3.34M 23.14M 8.91M 116M 8.99M 8.8M 369M
Net Debt 1.6B 238M 204M 193M 176M 328M 22.73B 331M 2.3B 884M 11.53B 893M 873M 36.61B 860M 128M 110M 104M 94.76M 177M 12.26B 179M 1.24B 477M 6.22B 481M 471M 19.74B
Logo Realcan Pharmaceutical Group Co., Ltd.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
Employees
2,407
Date Price Change Volume
26-09-09 CN¥3.150 -2.48% 67,869,820
26-09-09 CN¥3.230 -3.87% 74,019,577
26-09-08 CN¥3.360 +3.07% 97,751,501
26-09-07 CN¥3.260 +1.24% 65,308,478
26-09-04 CN¥3.220 +0.94% 99,189,994
  1. Stock Market
  2. Stocks
  3. 002589 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!